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Abstract Expression of microRNAs is altered in cancer.
Circulating miRNA level assessed in body fluids commonly
reflects their expression in tumor cells. In leukemias, however,
both leukemic and nonleukemic cells compose circulating
miRNA expression profile of peripheral blood. The latter
contribution to extracellular miRNA pool may result in
specific microenvironmental signaling, which promotes
proliferation and survival. In our study, we used qT-PCR to
assay peripheral blood serum of 22 chronic lymphocytic
leukemia (CLL) patients for the expression of 84 miRNAs
associated with activation and differentiation of B and T lym-
phocytes. Results were analyzed regarding the most important
prognostic factors. We have found that the general expression
of examined miRNAs in CLL patients was lower as compared
to healthy volunteers. Only miR-34a-5p, miR31-5p, miR-
155-5p, miR-150-5p, miR-15a-3p, and miR-29a-3p were
expressed on a higher level. Alterations of expression
observed in CLL patients involved miRNAs associated both
with B and T lymphocyte differentiation and activation. The
most important discriminating factors for all functional
miRNA groups were trisomy 12, CD38 expression, B2M
level, WBC, and NOTCH1 gene mutation. Correlation of
expression of miRNAs related to T lymphocytes with prog-
nostic factors proves their supportive function in a leukemic
microenvironment. Further studies utilizing a larger test group
of patients may warrant the identification of circulating
miRNAs that are key players in intercellular interactions and
should be considered in the design of microenvironment-
targeted therapies.
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Introduction
Chronic lymphocytic leukemia (CLL) is one of the most
common leukemias of the elderly. It is characterized by the
accumulation ofmature leukemic B lymphocytes in peripheral
blood, bone marrow, and lymphatic organs. Leukemic cells
are resistant to apoptosis, both spontaneous and induced with
antileukemic drugs. This phenomenon is associated with the
increased expression of antiapoptotic genes like BCL2 or
MCL1 and decreased proapoptotic proteins (i.e., TP53)
involvement [1]. The above abnormalities may result from
gene mutations and improper gene expression caused by post-
transcriptional alterations, or may be an indirect consequence
of prosurvival signaling from the microenvironment
composed of mesenchymal stromal cells, nurse-like cells
(NLCs), T lymphocytes, and others.
Clonal expansion of CLL lymphocytes begins with B cell
precursor stimulation by the antigen within or outside the
germinal centers, while the driver antigens targeting B cell
receptor are thought to be foreign or—more probably—autol-
ogous [2]. Clinically, CLL progresses with profound immuno-
deficiency, being the common cause of disease complications
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and death. The above facts point to the unique nature of CLL on
the crossroads of oncogenesis and autoimmunity [3]. T
lymphocyte population is involved as well; CLL patients
display Tcell dysfunctions and the observed higher than normal
absolute regulatory T cells (Tregs) number is considered
responsible for suppressing the antitumor immune response [4].
MicroRNAs (miRNAs) regulate gene expression at the
posttranscriptional level that make them the key players in all
biological processes [1]. By regulation of oncogenes and tumor
suppressors, miRNAs contribute to oncogenesis, and it was
proven that the miRNA expression pattern better characterized
cancer cells than messenger RNA (mRNA) expression, so
potentially they may serve as diagnostic, prognostic, and pre-
dictive factors [5–7]. What is more, intact miRNA molecules
freely circulate in body fluids like blood, milk, saliva, or urine
[8]. In many pathologic conditions, the circulating miRNA
level reflects the level of miRNA expression in affected tissue.
Once they were thought to be incidentally released from the
cells (i.e., from the cells dying by necrosis), now the new func-
tion of circulating miRNAs was discovered: they are actively
secreted molecules shuttling between cells as mediators [9].
Indeed, miRNAs may be transferred from cell to cell packaged
into exosomes, shedding vesicles or apoptotic bodies. Another
way of extracellular horizontal miRNA transfer is their binding
to lipoproteins (i.e., high-density lipoprotein, HDL) or to
proteins like AGO2 and NPM1 [10]. This way, the small
molecules may affect gene expression in target cells.
Studies in CLL microenvironment have shown that the
relation between leukemic and bystander cells is mutual, for
NLCs differentiate in vitro exclusively when cultured with
leukemic lymphocytes, not normal CD19+ B lymphocytes
[11]. To date, only indirect cell-cell contact and chemokines
produced by microenvironmental cells were considered
responsible for their interaction and observed protective prop-
erties toward CLL lymphocytes. However, it is more than
likely that specific miRNAs transferred from bystander cells
may also matter.
CLL may manifest as indolent, chronic disease or as
aggressive disorder associated with markedly shortened
lifespan [8]. Each type requires different treatment strategies.
As the Rai and Binet clinical staging systems turned out
insufficient for the precise stratification of patients to low-
and high-risk groups, intensive research in the field led to
the identification of several relevant molecular prognostic
and predictive factors [12, 13]. First gross discoveries includ-
ed selected recurrent chromosomal aberrations, i.e., trisomy
12, del 13q14, del 11q22.3-q23.1, and del 17p [14]. All of
these altered regions contain important genes whose contribu-
tion to CLL is more or less confirmed to date [15–17]. The
most common 13q14 deletion as the monoallelic sole abnor-
mality confers favorable prognosis, although it covers loci for
two miRNAs, miR-15a and miR-16-1, which target the BCL2
gene [17]. The presence of del 11q22.3-q23.1 (ATM locus) or
del 17p (TP53 locus) defines high-risk group patients charac-
terized by decreased overall survival (OS) and resistance to
chemotherapy based on alkylating agents [14, 18]. Since CLL
lymphocytes manifest low mitotic activity in vitro, chromo-
somal analyses were not very successful until the introduction
of fluorescent in situ hybridization (FISH) into routine diagnos-
tics. FISH significantly increased sensitivity of cytogenetics,
making it possible to identify chromosomal abnormalities in
up to 80 % of CLL patients [19].
Next, CLL prognostic milestones were mutations of the
genes encoding the variable part of the immunoglobulin heavy
chain (IgVH) [20]. Patients with unmutated IgVH genes were
shown to poorly respond to multiregimen chemotherapy and
had significantly shorter OS [20]. As IgVH gene sequencing is
complicated and time-consuming, more available surrogate
markers were identified. CD38 expression on ≥30 % CLL
lymphocytes or ZAP70 expression found in ≥20% of leukemic
cells is recognized as poor prognostic markers, partially
reflecting unmutated IgVH status [20–22].
Recent whole genome and whole exome sequencing
experiments brought other pieces of the puzzle for our under-
standing of CLL development. Many cryptic recurrent muta-
tions were found, involving TP53, NOTCH1, SF3B1, BIRC3,
XPO1, MYD88, KLHL6 gene, and others [23–26]. The
biological role of selected cryptic lesions in leukemogenesis
was reviewed before; they clearly influence the course of the
disease as well [27]. Mutations of TP53 gene commonly
coexist with 17p deletions; however, their sole presence
(4.5 % CLL patients) typifies poor survival similar to sole 17p
deletions and bi-allelic TP53 alterations [18]. This discovery
enables more precise stratification of patients, as well as the
knowledge concerning poor prognostic impact ofNOTCH1mu-
tation, typically coexisting with trisomy 12, the chromosomal
aberration which otherwise confers intermediate prognosis for
patients with mutated IgVH genes [28].
Some studies formulate new CLL classifications based
on genetic findings. Rossi and colleagues recognize four
prognostic groups (high, intermediate, low, and very low
risk) with 10-year survival 29, 37, 57, and 69.3 %, respective-
ly [26]. They integrated cytogenetic and mutational analysis
considering del 13q14, deletion or mutation of TP53, trisomy
12, del 11q22-q23 together with NOTCH1, BIRC3, and
SF3B1 mutations [26]. The status of IGVH and TP53 genes
is considered crucial in recent five-variable International
Prognostic Index for Patients with CLL (CLL-IPI) proposed
by The International CLL-IPI working group [29]. There
are also some trials of miRNA profiling in CLL patients
to select these of prognostic significance [30]. The elegant
study by Visone and coworkers presents the results of
miRNA expression assessment in the context of chromo-
somal abnormalities [31]. All factors considered to date,
however, are intrinsic factors, inseparably associated with
leukemic lymphocytes.
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Despite the progress in the design of treatment strategies,
the aggressive form of CLL is still incurable; thus, the research
in the field of microenvironmental factors concurring in
leukemogenesis is important both for diagnostic and therapeutic
purposes [1].
The aim of the presented study was the assessment of
expression of circulating miRNAs most relevant to specific
stages of T cell and B cell development in CLL patients. The
results were then related to clinical and biochemical patients’




With informed consent, in accordance with the Declaration of
Helsinki and approval from the Medical University of Lublin
Bioethics Committee (KE-0254/155/2010 and KE-0254/118/
2011), peripheral blood was obtained from 36 consecutive,
treatment naive patients, diagnosed with CLL at the
Department of Hematooncology and Bone Marrow
Transplantation, Medical University of Lublin. After serum
miRNA isolation, 22 patients (10 women and 12 men) were
qualified for further analyses.
By reference to the Rai classification, seven patients were
at stage 0, seven at stage I, six at stage II, one at stage III, and
one patient at stage IV. Basic clinical and hematological
parameters are shown in Table 1, and detailed patients’ char-
acteristics are reported in Supplementary Table S1. Peripheral
blood from eight healthy volunteers (three women and five
men, aged 22–45) attending the Regional Blood Donation and
Hemotherapy Center in Lublin served as the reference sample.
Immunophenotyping
Whole blood specimens collected in EDTA (Sarstedt tubes,
Sarstedt, Germany) were immunophenotyped by flow cytometry
with FACSCalibur apparatus equipped with the CellQuest
software (Becton-Dickinson Immunocytometry System);
10,000 cells for each sample were assessed after incubation
with monoclonal mouse antihuman CD5-PE, CD19-PE-Cy5,
CD23-FITC, CD38-FITC, and ZAP70 antibodies along with
appropriate isotype controls (all from BD Bioscience).
Antibodies were applied at 1 μg/100 μL of cell suspension
(1 × 106 cells in 1 % BSA/PBS), and samples were processed
according to the manufacturer’s instructions.
Cell cultures and FISH analysis
Peripheral blood samples were collected inMonovette heparin
tubes (Sarstedt, Germany). Mononuclear cells were isolated
Table 1 Characteristics of CLL patients
N = 22 (100 %)
Sex
Male 12 (54 %)






0 7 (32 %)
I 7 (32 %)
II 6 (27 %)
III 1 (4.5 %)





















CD38+ 7/22 (31.8 %)
ZAP70+ 8/22 (36 %)
IGVH-mut 6/21 (28.6)
NOTCH1-mut 5/22 (22.7 %)
TP53-mut 5/21 (23.8 %)
FISH
Normal 2/22 (9 %)
del13q14/RB1 4/22 (18 %)
del13q14.3/D13S319 15/22 (68 %)
del17p/TP53 8/22 (36 %)
del11q/ATM 8/22 (36 %)
+12 6/22 (27 %)
WBC white blood cells count, ALC absolute lymphocyte count, PLT
absolute platelet count, B2M beta-2-microglobulin, LDH lactate dehydro-
genase, mut mutation
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by gradient density centrifugation (Lymphoprep™, AXIS-
SHIELD). Stimulated cell cultures were prepared using
RPMI 1640 medium with L-glutamine supplemented with
20 % FCS vol/vol (Biomed Poland), 10 U/mL penicillin,
and 50 μg/mL streptomycin (Gibco, Invitrogen). The cultures
were stimulated with pokeweed mitogen, 2.5 μg/mL (PWM,
Sigma), or TPA, 10 ng/mL (12-O-tetradecanoylphorbol 13-
acetate, Sigma-Aldrich). Cells were cultured at 37 °C in a
humidified incubator in 5 % CO2 atmosphere for 72 h and
5 days. The cultures were harvested conventionally, and the
metaphase spreads were stained using GTG and RHG banding
techniques.
FISH was performed utilizing the following probes: Vysis
D13S319 (13q14.3), Vysis LSI 13 (RB1), Vysis LSI ATM,
CEP12, and Vysis LSI TP53 SpectrumOrange/CEP 17
SpectrumGreen Probe (all from Abbott Molecular, USA),
strictly according to the manufacturer’s instructions; 200
interphase cells were examined for each patient. The
established cutoff levels were as follows: 5 % positive cells
for trisomy 12, 8 % for del(13)(q14.3) and RB1 locus deletion,
and 9 % for both del(11)(q22.3) and del(17)(p13.1).
DNA isolation and sequencing
Genomic DNA was extracted from 200 μL peripheral blood
samples collected in EDTAwith GeneMATRIX Quick Blood
DNA Purification Kit (EURx, Poland), according to the
manufacturer’s manual. DNA quality and quantity were
assessed by means of NanoDrop 2000 spectrophotometer
(ThermoScientific) and by agarose gel electrophoresis (2 %
agarose in TBE). For further investigation, samples containing
nondegraded, high molecular weight DNA at the concentra-
tion of at least 100 ng/μL, with A260/A280 ratio between 1.8
and 2.0, were used.
The most common NOTCH1 mutations located in frag-
ment of exon 34 (c.7544-7545delCT, c.7225C>T,
c.7369C>G, c.7446delC, c.7392delC, c.7321C>T,
c.7507C>T, c.7244-7271del28) were analyzed by direct
sequencing. DNA was amplified with high fidelity
Advantage HD polymerase (Clontech). All primers and
conditions were designed at the Department of Cancer
Genetics, Medical University of Lublin (sequences and
detailed conditions are available on request).
TP53 mutational status was determined by automated
sequencing of exons 4–10, strictly according to the protocol
published by the International Agency for Research on Cancer
(IARC) [32, 33]. For PCR reactions, 50 ng DNA and Color
Perpetual OptiTaq PCR Master Mix (EURx, Gdansk, Poland)
were used.
The immunoglobulin heavy chain variable (IGHV) muta-
tion status was determined by DNA amplification with poly-
merase chain reaction (PCR) using six different sense primers
specific for framework region (FR) 1 consensus family
(IGHV1–IGHV6) and one antisense primer complementary
to the germline JH regions, according to the BIOMED-2
Concerted Action protocols [34]. The seven IGVH families
were amplified in six individual PCRs. PCR products were
separated on 2 % agarose gel, cut out, and purified using
QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany).
Purified PCR products were directly sequenced using an
ABI PRISM BigDye Terminator v3.1 cycle sequencing kit
(Applied Biosystems, Foster City, CA, USA), following the
manufacturer’s instructions by means of an automatic ABI
3500 Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA). The percentage of hypermutations was calculated.
Each clonal DNA IGHV sequence was aligned with the
closest germline sequence using the international
ImMunoGeneTics information system (IMGT, http://www.
imgt.org/). The sequences with a germline homology 98 % or
higher were considered unmutated, and those with a homology
less than 98 % as mutated.
MicroRNA isolation and profiling
Peripheral blood samples were collected in S-Monovette
Serum Gel Z tubes (Sarstedt, Germany) and immediately
placed at 4 °C for 30–40min, in order to facilitate coagulation.
Samples were then centrifuged at 2000 rpm for 20 min at RT
to spin down the clot. The separated supernatant was carefully
transferred into fresh Eppendorf tubes and centrifuged again at
4000 rpm for 10 min at 4 °C. Carefully collected transparent
serum samples were then aliquoted into fresh tubes and stored
at −80 °C.
Total RNA including miRNA and small RNA fraction was
isolated using miRNeasy Serum/Plasma Kit (Qiagen) accord-
ing to the manufacturer’s instructions. Serum/Plasma Spike-In
Control (Qiagen) was added to provide system for normaliza-
tion. Quality and quantity of RNAwere assessed by means of
NanoDrop 2000. Samples containing at least 5 ng/μL of
RNA, with A260/A280 ratio between 1.7 and 2.1, were used
for further analysis. Isolated RNAwas stored at −80 °C.
MicroRNA expression profiling was performed by means
of T-Cell & B-Cell Activation miScript miRNA PCR Array
(Qiagen, cat. # MIHS-111Z), using primers for 84 preselected
miRNAs, important for differentiation, maturation, and
activation of B and T lymphocytes (see Supplementary
Table S3 for the full list).
Complementary DNA (cDNA) synthesis was carried out
utilizing miScript II RT Kit (Qiagen) on 125 ng of RNA in
20 μL of final volume. HiSpec buffer (Qiagen) was used for
the selective conversion of mature miRNAs. After reverse
transcription, reaction samples were stored at −20 °C. For
qT-PCR, the miScript® SYBR®Green PCRKit together with
T-Cell & B-Cell Activation miScript miRNA PCR Array
(both fromQiagen) were used according to the manufacturer’s
instructions. Each RT sample was diluted with 200 μL RNase
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free water, and 100 μL of the obtained cDNA solution was
used as template for qT-PCR performed on a 96-well plate.
The following snoRNAs—SNORD95, SNORD96A, and
RNU6B/RNU6-2—were used as a normalization control for
the array data. Total qT-PCR reaction volume was 25 μL/well.
qPCR was performed by means of 7500 Fast Real-Time PCR
System (Applied Biosystems, USA). All reactions were run in
duplicate.
Amplification curves were analyzed to define Ct (threshold
cycle). The melting curve analysis was implemented. The
relative expression of serum miRNA in CLL patients was
assessed with the 2−ΔΔCt method, using pooled miRNA from
healthy donors as the reference [35].
Statistical analyses
Statistical analyses were performed with Statistica 10.0
PL software and a free accessible R statistical package
(www.R-project.org).
For array data analysis, the original data were normalized
and expressed in logarithmic scale. For comparison of pairs of
groups, Welch’s corrected t test was applied. The significance
of diversification in the two groups was assessed by a variance
analysis test (test F).
For the other analyses, the normality of data distribution was
tested by means of the Shapiro-Wilk test. Descriptive statistical
analysis was performed utilizing median, minimal, and maxi-
mal values. The significance of differences between dependent
samples was tested by means of the Wilcoxon matched pairs
test and Kruskal-Wallis test and differences between
independent samples were tested by the Mann-Whitney
U test. The strength of interdependency of two variables
was expressed with Spearman’s rank correlation coefficient (R).
The differences were considered statistically significant
with P values less than 0.05.
Results
Clinico-molecular characteristics and cytogenetic findings
The final study group included 22 CLL patients. Their age
ranged 50–85 (median 64), WBC ranged 14.29–742 × 109/L
(median 35.72×109/L), absolute lymphocyte count ranged
7.06–721 × 109/L (median 28.52×109/L), and platelet count
ranged 124–373 × 109/L (median 199.0×109/L) (Table 1,
Online Resource Table S1). Seven patients were considered
as CD38+ (the cutoff 30 % of positive cells) and eight patients
as ZAP70+ (the cutoff 20 % of positive cells). In compliance
with the Rai stage of the disease, 7 patients were in the favor-
able prognostic group, 13 patients in the intermediate, and 2 in
the adverse prognostic group. The time of follow-up was
30 months; in 10/22 patients (45.5 %), treatment has to be
initiated and time to treatment (TTT) ranged from 0 to
27 months. Three patients died of CLL during follow-up;
2.5-year survival was 80.36 %.
Successful IGVH gene sequencing was performed in
21 patients of whom 6 (28.6 %) were identified with
mutation (the concordance with germinal sequence
ranged 89.45–95.77 %).
NOTCH1 mutation c.7544-7545delCT (P2515fs), located
in exon 34, was found in five patients (22.7 %) (Fig. 1). Other
NOTCH1 mutations within this region were not identified.
IGVH and NOTCH1 mutations were mutually exclusive
(Online Resource Table S1).
TP53mutations were found in 5 cases out of 21, including
four substitutions (c.518T>A, c.673T>C, c.919C>G, c.673-
36G>C) and a deletion c.778del26, as compared to reference
sequence NM_000546.5.
FISH was aimed at the identification of four typical CLL
aberrations (del11q, del13q14, del17p, and trisomy 12). As
the prognosis of CLL patients was found to differ depending
on the type of chromosome 13q deletion, we have decided to
check both for deletion at D13S319 (13q14.3) and at RB1
locus [36].
FISH analysis revealed normal karyotype in two
patients (Table 1, Table S1). Single aberration was identi-
fied in 7 patients (32 %), two coexisting aberrations were
found in 9 patients (41 %), three in 3 patients, and 2
patients carried four aberrations simultaneously. We have
found the deletion of D13S319 region (13q14.3) in 15
patients (68 %), while the deletion of RB1 gene locus
(13q14) was identified in 4 patients. The deletion of
TP53 gene locus (17p13) and the deletion of ATM gene
locus (11q22-q23) were present in eight patients each.
Trisomy of chromosome 12 was found in six patients,
and in three of them, NOTCH1 mutation was identified
(Table 1, Online Resource Table S1).
Two patients with TP53 deletion identified by FISH were
found to carry mutation of the other allele of the gene.
Altogether, 11/22 patients were characterized by mutation
and/or deletion of the TP53 gene (Table S1).
MiRNA expression profiling
General serum miRNA expression of CLL patients is lower
than their normal counterparts
Serum expression of the analyzed circulating miRNA in CLL
patients was found to be much lower as compared with
healthy individuals (Online Resource Table S2). Considering
mean expression values, only 6 out of 84 analyzed miRNAs
(7.14 %) were expressed at higher than normal level, while
expression of two (2.38 %) was similar to normal. Among the
miRNAs of the highest expression were miR-34a-5p (mean
6.6476 compared to 1 in normal individuals, median 1.8623),
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miR-31-5p (mean 4.4744, median 1.9298), miR-155-5p
(mean 3.6579, median 1.5426), miR-150-5p (mean 1.5197,
median 0.8621), miR-15a-3p (mean 1.4331, median
0.6042), and miR-29a-3p (mean 1.2440, median 0.9617)
(Table 2).
Serum miRNAs of the lowest expression included miR-
147a (mean 0.0156, median 0.0025), miR-184 (mean
0.0328, median 0.0000), and miR-326 (mean 0.0690, median
0.0219) (Table 3).
Prognostic factors mostly discriminating the general miRNA
expression include the expression of CD38, status
of chromosome 12 and RB1 locus, as well as patients’ age
and B2M level
We analyzed circulating miRNA expression with regard to
clinico-molecular and cytogenetic findings. There were no
statistically significant differences between male and female
patients. When we divided patients depending on age (up to
65 years and over), nine miRNAs were found expressed
differently. The expression of miR-16-5p, miR-17-5p, miR-
195-5p, miR-20a-5p, and miR-25-3p (in descending order)
was significantly higher in younger patients, while miR-17-
3p, miR-181c-5p, miR-181d-5p, and miR-182-5p expression
was higher in older patients (Table 4). Three miRNAs—miR-
125b-5p, miR-145-5p, and miR-99a-5p—were expressed at a
lower level in patients with advanced disease (Rai stadium 2–
4) when compared to patients diagnosed with Rai 0 and 1. We
also observed the difference in three miRNA expression be-
tween patients depending on WBC: miR-125-5b, miR-128-
3p, and miR-99a-5p were expressed lower in patients with
WBC over 35 × 109/L. In patients with high beta-2-
microglobulin (B2M) level (3.0 mg/L and over), nine
miRNAs were expressed lower than in the group of normal
B2M: miR-7c, miR-125b-5p, miR-132-3p, miR-146b-5p,
miR-18a-5p, miR-28b-3p, miR-365a-3p, miR-98-5p, and
miR-99a-5p (Table 4). Only one miRNA was expressed dif-
ferently between patients with LDH activity below or over
480 IU/L—lower miR-423-5p expression was observed in
the latter group.
CD38 expression was the factor significantly differentiating
CLL patients, and 20/84 (23.8 %) analyzed miRNAs were
expressed lower in the CD38+ group: let-7a-5p, miR-7c,
let-7d-5p, let-7e-5p, let-7f-5p, miR-101-3p, miR-130b-3p,
miR-146b-5p, miR-15a-5p, miR-182-5p, miR-18a-5p,
miR-199a-5p, miR-19b-3p, miR-210-3p, miR-28b-3p,
miR-29a-3p, miR-29c-3p, miR-331-3p, miR-335-5p, and
miR-34a-5p (Table 4). Only one miRNA, miR182-5p,
differentiated patients as ZAP70 positive and negative,
being expressed at a lower level in the latter group.
Surprisingly, there were almost no differences in general
miRNA expression when molecular prognostic factors were
considered: miR-28b-3p was expressed lower in IGVH-
unmutated patients, while two miRNAs miR-132-3p and
miR-146-5p were expressed lower in patients with the wild




Fig. 1 Exemplary sequencing results of NOTCH1 gene in CLL patients. Arrows mark the site of mutation within the NOTCH1 gene (exon 34)
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Considering cytogenetic prognostic factors, the one that
most significantly determinatedmiRNA expression was trisomy
12. In patients lacking this aberration, 14 (16.66 %) miRNAs
were expressed at a lower level as comparedwith the +12 group:
miR-128-3p, miR-132-3p, miR-15a-3p, miR-15b-5p, miR-
181b-5p, miR-191-5p, miR-19a-3p, miR-19b-3p, miR-23a-3p,
miR-25-3b, miR-27a-3p, miR-30c-5p, miR-574-3p, and miR-
92a-3p (Table 4).
RB1 gene locus deletionwas associatedwith higher expres-
sion of eight miRNAs: miR-128-3p, miR-132-3p, miR-15a-
3p, miR-15b-5p, miR-181b-5p, miR-191-5p, miR-19a-3p,
miR-19b-3p, miR-23a-3p, miR-25-3b, miR-27a-3p, miR-
30c-5p, miR-574-3p, and miR-92a-3p. Additionally, one
miRNA, miR-326, was expressed at a lower level in patients
carrying RB1 deletion. Surprisingly, the deletion of the region
D13S319 localized downstream the RB1 locus on chromo-
some 13 did not affect the circulating miRNAome at all.
There was also no significant correlation between del13q14.3
and the expression of miR-15a-5p or miR-16-5p as assessed
using Spearman’s coefficient of correlation (rs = −0.10426
and rs = 0.05958, respectively).
In patients with TP53 deletion/mutation, two miRNAs
were expressed lower (miR-130b-3p and miR-15a-5p) than
in patients with wtTP53. Contrarily, in the latter group, lower
expression of miR-155-5b was observed. Low expression of
five miRNAs (miR-139-5p, miR-181d-5p, miR-182-5p, miR-
31-5p, and miR-365a-3p) characterized patients with 11q/
ATM deletion.
Some miRNAs are differentially expressed across several
prognostic groups
Looking for differentiating miRNAs common for different
prognostic groups, we have found miR-182-5p differentially
expressed in four groups (patients older than 65, CD38+,
ZAP70+, with del11q) (Table 5). Five miRNAs were differ-
entially expressed in three groups: miR-28b-3p (patients with
high B2M, CD38+, IGVH-unmutated), miR-15a-5p (patients
CD38+, with TP53 deletion/mutation, and trisomy 12), miR-
125-5b and miR-99a-5p in the same prognostic groups (pa-
tients in advanced stage—Rai 2–4, patients with high B2M,
patients with highWBC), and miR-132-3p (patients with high
B2M, NOTCH1 mutation and trisomy 12) (Table 5). Three
other miRNAs, miR-7c, miR-15a-5p, andmiR-155-5p, shared
differences in expression between two prognostic groups.
The expression of miRNAs related to T and B cell
differentiation and activation is associated with CLL
prognostic factors
We then analyzed circulating miRNA expression regard-
ing their functional groups with respect to B and T cell
differentiation, T cell activation, and miRNAs differentially
expressed in Tregs. Several functional miRNA groups were
considered: (1) B cell differentiation: a. naive, b. germinal
center, c. memory; (2) Tcell differentiation: a. double negative
(CD4−/CD8−), b. double positive (CD4+/CD8+), c. CD4+
naive, d. CD8+ naive, e. CD8+ effector, f. CD8+ memory;
(3) T cell activation; and (4) Tregs. The complete list of
grouped miRNAs according to manufacturer of the assay is
presented in Online Resource Table S3.
Alterations in miRNA expression involved all functional
groups, and most of them correlate with prognostic factors.
Some of the most adverse prognostic factors in CLL
(i.e., age >65 years, Rai stages 2–4, WBC >35 × 109/
L, CD38+ cells >30 %, B2M >3 mg/L, LDH >480 IU/L,
del 11q and lack of IGVH mutation) were correlated with the
decrease of miRNA expression (Tables 6 and 7). Only muta-
tion of NOTCH1 gene and male sex were found to correlate
with the increase of expression of the miRNAs analyzed.
Status of chromosome 12 was the factor that affected the
expression of miRNAs from all functional groups. In patients
carrying trisomy 12, their expression was significantly higher
as comparedwith patients without this aberration. The number
Table 2 Circulating miRNAs of
highest expression in CLL
patients (fold change compared to
the reference sample)
miRNA Number Mean Median Minimum Maximum Std. deviation
miR-34a-5p 22 6.647689 1.862355 0.000000 61.91293 14.16198
miR-31-5p 22 4.474437 1.929808 0.000000 26.27631 7.50078
miR-155-5p 22 3.657947 1.542619 0.000000 21.42856 4.858174
miR-150-5p 22 1.519764 0.862124 0.006600 8.65041 1.952950
miR-15a-3p 22 1.433167 0.604238 0.000000 12.88144 2.701575
miR-29a-3p 22 1.244012 0.961733 0.045252 5.97998 1.32323
miR-574-3p 22 0.968155 0.299874 0.028972 6.78702 1.58355
miR-29c-3p 22 0.929145 0.645566 0.009438 4.14237 0.97865
Expression values were presented as the logarithm of R to the base 2, where R was calculated as
follows: R = 2−ΔΔCt , ΔΔCt =ΔCt of CLL patient −ΔCt of normal individuals, every ΔCt = Ct of
miRNA examined − Ct of endogenous control, 1 −mean expression in pooled miRNAs of normal
individuals
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of CD38-positive cells and B2M level were important as
well—the expression of miRNAs from all functional groups
except one (CD4+ naive and CD8+ memory associated, re-
spectively) was significantly lower in patients with more than
30 % of CD38+ cells and high B2M (Table 6). Among well-
known prognostic factors clearly associated with circulating
miRNA expression, we have found also WBC, ATM gene
status, and age—in all cases, patients classified to the adverse
prognostic groups were identified with decreased miRNA
expression.
Considering expression of miRNAs grouped into
functional groups, IGVH gene status was also identified
as an important differentiating factor: miRNA expres-
sion was significantly lower in unmutated patients in 7
out of 11 functional groups considered (Tables 6 and 7).
As mentioned before, NOTCH1 mutation was associated
Table 3 Circulating miRNAs of
lowest expression in CLL patients
(fold change compared to the
reference sample)
miRNA Number Mean Median Minimum Maximum Std. deviation
miR-147a 22 0.015611 0.002544 0.000000 0.21399 0.046501
miR-184 22 0.032830 0.000000 0.000000 0.62236 0.132337
miR-326 22 0.060900 0.021956 0.000000 0.83752 0.17533
miR-18a-5p 22 0.103611 0.056592 0.000000 0.41750 0.113735
miR-195-5p 22 0.107020 0.057505 0.000458 0.54184 0.127800
miR-25-3p 22 0.109736 0.062301 0.001780 0.52281 0.13023
let-7d-5p 22 0.112145 0.058179 0.006802 0.442157 0.119731
miR-130b-3p 22 0.113208 0.062630 0.000000 0.461458 0.121767
miR-191-5p 22 0.116295 0.065128 0.004588 0.60537 0.150365
miR-30c-5p 22 0.127434 0.052519 0.008106 0.44780 0.14150
let-7e-5p 22 0.131160 0.063212 0.012399 0.513795 0.138210
miR-19a-3p 22 0.132547 0.087024 0.005614 0.48952 0.135557
miR-17-5p 22 0.132640 0.087608 0.005313 0.48162 0.128858
miR-16-5p 22 0.132781 0.079348 0.000449 0.77485 0.175928
miR-30b-5p 22 0.136220 0.076458 0.006022 0.42131 0.13321
miR-30d-5p 22 0.136391 0.075910 0.003105 0.56710 0.15640
miR23b-3p 22 0.137499 0.064416 0.003837 0.62679 0.16386
let-7f-5p 22 0.146194 0.072787 0.011085 0.552243 0.160592
let-7a-5p 22 0.147019 0.088026 0.005797 0.510367 0.155073
miR-182-5p 22 0.153754 0.052493 0.000000 1.10934 0.254892
miR-26a-5p 22 0.161983 0.087658 0.001916 0.67649 0.17815
miR-98-5p 22 0.173266 0.039254 0.000000 1.06964 0.29938
miR-142-5p 22 0.174660 0.086560 0.006512 0.61231 0.190252
miR-26b-5p 22 0.181229 0.098017 0.005669 0.71576 0.19998
miR222-3p 22 0.189829 0.091111 0.000000 1.13503 0.26830
miR-181c-5p 22 0.196126 0.099759 0.000000 0.94699 0.244802
miR-15b-5p 22 0.199360 0.078987 0.008995 1.47413 0.343739
miR-181b-5p 22 0.207683 0.088729 0.000000 0.90124 0.264372
miR-214-3p 22 0.212431 0.066792 0.000000 1.65352 0.36579
miR-24-3p 22 0.224084 0.095890 0.000000 1.39993 0.33267
miR-132-3p 22 0.237720 0.090168 0.000000 1.859543 0.402654
miR-27b-3p 22 0.244229 0.096800 0.027010 1.32214 0.36012
miR-17-3p 22 0.300520 0.084771 0.000000 1.40011 0.401672
miR-92a-3p 22 0.390319 0.049988 0.000600 5.51859 1.20007
miR-93-5p 22 0.439960 0.071626 0.000000 7.10019 1.49466
miR223-3p 22 0.446638 0.073717 0.000000 5.64799 1.18569
Expression values were presented as the logarithm of R to the base 2, where R was calculated as
follows: R = 2−ΔΔCt , ΔΔCt =ΔCt of CLL patient −ΔCt of normal individuals, every ΔCt = Ct of
miRNA examined − Ct of endogenous control, 1 −mean expression in pooled miRNAs of normal
individuals
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with an increased miRNA expression, and this was observed
for all functional groups except CD4+ naive, CD8+ effector,
and CD8+ memory T cells (Table 6).
The largest number of differentially expressed miRNAs
between CLL prognostic groups is observed in these
associated with B cell differentiation, T cell activation,
and double negative T cells
Significant differences between CLL prognostic groups were
found for expression of all groups of miRNAs associated with
B cell differentiation: germinal center cells, naive cells, and
memory B lymphocytes (Table 6). The expression of them all
was clearly associated with patients’ age, WBC, CD38 status,
B2M level, LDH activity, and the presence of NOTCH1
mutation and trisomy 12 (Table 7).
Of the T cell-associated miRNAs, the most distinct expres-
sion differences involved molecules related to CD4−/CD8−
cells and CD4+ naive cells as well as associated with T cell
activation and differentially expressed in Tregs. Prognostic
factors most important for all T-associated miRNA expression
involved WBC, CD38 status, B2M level, and trisomy 12
(Tables 6 and 7).
Circulating miRNA expression is associated with the need
of treatment initiation
We have found significant differences in the expression of
some miRNAs between patients classified to the Bwatch and
wait^ group and patients with indications to treatment initia-
tion (Table 4). Most of the differently expressed miRNAs
were associated with germinal center B cells (miR-181a-5p,
miR-17-3p, miR-98-5p) and T cell activation/Tregs (miR-
181c-5p); their expression was lower in patients requiring
treatment.
Discussion
miRNAs are nowwell-known factors which may contribute to
the leukemogenesis and affect the clinical course of chronic
lymphocytic leukemia [1, 37]. Historically, CLL was the first
among human cancers discovered to clearly associate with
alterations of miRNA expression. Deletion of miR-15a and
miR-16 in leukemic cells was found to result in BCL-2 gene
overexpression leading to their prolonged survival and resis-
tance to apoptosis [16]. The exact role of miR-15/16 in CLL
was reviewed in detail by Pekarsky and Croce [17]. Many
studies addressed miRNA expression in lymphocytes of
CLL patients and tested its correlation with clinical and prog-
nostic parameters [38–41]. New possibilities have opened
with the discovery of circulating miRNAs. Easily available
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convenient biomarkers in solid tumors; however, one cannot
underestimate their role in leukemias. Once released from
leukemic cells, miRNAs may potentially affect the cells that
comprise the microenvironment and vice versa. Circulating
miRNAmolecules packaged into exosomes or associatedwith
specific proteins may be engulfed by the recipient cell or may
target its receptors. Both scenarios end up with the effect on
recipient cell gene expression [10]. The principle of this
phenomenon was described as horizontal transfer of
miRNAs and is now recognized as the new form of intercel-
lular communication [9].
The comparative study by Moussay and colleagues has
shown that, like in solid tumors, the expression of most
circulating miRNAs in CLL patients reflects their expres-
sion in leukemic cells [37]. It is not quite obvious, be-
cause in leukemias other blood and bone marrow cells
may also impact the expression pattern. The level of cir-
culating miRNA expression in CLL, however, is de-
creased as compared to miRNA expression assessed in
leukemic lymphocytes; this phenomenon was also ob-
served in our study [37].
We analyzed serum expression of selected miRNAs asso-
ciated with differentiation and activation of B and T lympho-
cytes. Based on the assessment of 84 miRNAs, the general
serum expression in CLL patients was found to be lower in
comparison to normal individuals (Supplementary Table S2).
Interestingly, three miRNAs of the lowest expression in our
series of patients (miR-147a, miR-184, and miR-326, Table 3)
are classified as molecules associated with T cell, not B cell
differentiation. Expression of none of the above miRNAs
correlated with prognostic factors. To date, there is no data
concerning their role in CLL and neither their loci are associ-
ated with breakpoints typical for this disease. However, they
all are thought to function as tumor suppressors (TS), at least
in some cancer types [42–50].
The gene encoding miR-147a is localized at 9q33.2. It is
classified to miRNAs associated with CD8 effector cells. In
mice, miR-147 is induced upon stimulation of Toll-like recep-
tors and functions as a negative regulator of inflammatory
cytokine expression in macrophages [42]. Lee and colleagues
reported that transfection of miR-147 into colon cancer cells
(HCT116, SW480) and lung cancer cells (A-549) resulted in
mesenchymal-to-epithelial transition (MET) induction and G1
cell cycle arrest. Additionally, it led to reversion of the native
drug resistance of the colon cancer cell line HCT116 to gefitinib
[42]. TS function of miR-147 was also described in breast
cancer, where it targets EGFR-driven cell cycle network pro-
teins and inhibits cell cycle progression and proliferation [44].
miR-184 gene locus was mapped to 15q25.1. Its expression
is related to CD4+ naive cells. miR-184 was found to be highly
expressed in umbilical cord CD4+ cells, where it
inhibits NFAT1 protein synthesis thus contributing to the early
adaptive immune response [45]. Zhen and coworkers re-
ported that miR-184 targeted and inhibited BCL2 and CMYC
transcripts in nasopharyngeal carcinoma [46]. In neuroblasto-
ma,miR-184was found to targetAKT2 kinase, amember of the
































Naive 0.0018 0.0034 <0.0001 0.0008 0.0103 0.0376 0.0011 0.0130 <0.0001
Germinal center <0.0001 <0.0001 <0.0001 <0.0001 0.0117 0.0115 0.0125 – <0.0001
Memory 0.0005 0.0002 0.0001 0.0024 0.0440 – 0.0462 0.0111 <0.0001
T cell differentiation
Double negativea 0.0008 <0.0001 <0.0001 <0.0001 0.0020 0.0050 0.0006 0.0033 <0.0001
Double positiveb – – 0.0001 0.0007 – 0.0169 0.0347 0.0019 0.0006
CD4+ naive – 0.0063 – 0.0059 – – – – 0.0151
CD8+ naive 0.0052 0.0064 <0.0001 0.0008 0.0124 0.0317 0.0189 0.0081 <0.0001
CD8+ effector – – 0.0024 0.0009 – – – – 0.0013
CD8+ memory 0.0005 0.0135 0.0007 – – – – – <0.0001
T cell activation <0.0001 <0.0001 <0.0001 <0.0001 0.0193 0.0051 0.0009 0.0017 <0.0001
Tregs <0.0001 <0.0001 0.0002 0.0003 – 0.0388 0.0093 0.0006 0.0041
For data analysis, the Kruskal-Wallis test was used. Dashes stand for no statistical differences. See Table 6 for the direction of the particular difference
mut mutated, unmut unmutated, wt wild type, n12 normal number of chromosomes 12
a CD4−/CD8−
b CD4+/CD8+
44 Ann Hematol (2017) 96:33–50
AKT family of proteins that are activated by the phos-
phatidylinositol 3′ kinase (PI3K) pathway. Ectopic upregulation
of miR-184 resulted in apoptosis of neuroblastoma cells [47].
The gene for miR-326 localizes at 11q13.4. Like miR-184,
miR-326 is linked to CD4+ naive cells. As a suppressor of the
Hedgehog signal transduction pathway, it has been demon-
strated to control the development of cerebellar neuronal
progenitor and tumor cells [48]. The decreased miR-326 ex-
pression in glioma was found to be significantly associated
with advanced pathological grade. The study by Kefas and
colleagues showed that the expression of miR-326 in glioma
inhibited NOTCH protein synthesis, but concurrently was
suppressed by NOTCH, indicating a feedback loop [49].
What is more, miR-326 transfection reduced glioma cell
tumorigenicity in vivo. A decrease in miR-326 expression
was found in advanced breast cancer cells and irreversibly
correlated with the expression of multidrug resistance associ-
ated protein 1 (MRP1) contributing to chemoresistance [50].
Considering miRNAs that were expressed on the highest
level in CLL patients studied (i.e., miR-34a-5p, miR-31-5p,
miR-155-5p, miR-15a-3p, andmiR-29a-3p), all but one (miR-
31-5p) were associated with B cell differentiation and homeo-
stasis (Table 2, Supplementary Table S3). In several studies,
their expression was shown to discriminate between CLL
patients and healthy individuals, and they all have been
corroborated as important for CLL development and clinical
course of the disease [1, 37, 51–54]. Among others, their
confirmed targets include BCL2 (miR-34a, mir-29a, miR-
15), MCL1 (miR-15a, miR-29a), TCL1 (miR-29a), BAK1
(miR-150, miR-29a), MYC (miR-34a), NOTCH1 and 2
(miR-34a), CMYB (miR-150, miR-155), TP53INP (miR-
155), ETS1 (miR-155), DICER1 (miR-29a), CDK6 (miR-
29a), SPI1 (miR-155), and FOXP1 (miR-34a); they were
reviewed by many authors [1, 37, 51, 52, 54].
The serum expression level of four of B cell-associated
molecules in our study—miR-34a-5p, miR-155-5p, miR-
150-5p, and miR-29a-3p—reflected their described cellular
expression; yet, it was proportionally lower [39–41]. Li and
colleagues reported overexpression of two miRNAs, miR-34a
and miR-155, in CLL lymphocytes, and defined it as a part of
activated B cell phenotype [40]. Cellular miR-34a expression
in CLL is higher in patients with intact TP53 pathway and
associates with longer time to treatment [55]. TP53 protein
induces expression of miR-34 family (miR-34a, locus at
1p36, miR-34b/34c, locus at 11q) and provokes TP53-like
responses like senescence, cell cycle arrest, and apoptosis
[55]. Fabbri and coworkers described the latter two miR-34
family members as the important part of miRNA/TP53 feed-
back circuitry involved in CLL pathogenesis [56]. However,
in our study, there was no correlation between serum miR-34a
expression and TP53 status. Tserel and coworkers described
significantly increased expression of miR-34a in peripheral
blood monocyte-derived macrophages [57]. Considering that
nurse-like cells, present in the circulation of CLL patients, are
thought to be monocyte-derived macrophages, it is possible
that they are responsible for high, TP53-independent expres-
sion of this molecule in the serum of tested patients [58]. An
important issue requiring further investigation is whether or
not leukemic lymphocytes may make use of extracellular
miR-34a. It is worth pointing out that miR-34a mimic,
MRX34, is the first miRNA mimic currently evaluated in a
multicenter phase I study in patients with hematological ma-
lignancies including CLL (ClinicalTrials.gov Identifier
NCT01829971) [59].
miR-155 expression in B lymphocytes was found to
discriminate between normal individuals, individuals with
monoclonal B cell lymphocytosis (MBL), and CLL patients;
its overexpression in the latter group is associated with aggres-
sive disease [60, 61]. Ferrajoli and colleagues demonstrated
the presence of miR-155 in circulating microvesicles of indi-
viduals with MBL and CLL, which may point to its role in
microenvironmental stimuli pathway [60]. Furthermore,
upregulation of miR-155 in B cells by microenvironmental
signals resulted in increased sensitivity to BCR ligation [61].
Contrarily, cellular expression of miR-15a-3p in CLL is
described to be low (and potentially correlated with miR-
15a/miR-16-1 deletion) [16]. In our study, the mean serum
miR-15a-3p expression in CLL patients was 1.433-fold of that
in normal individuals (Table 2), and the same discrepancy was
also noticed by Moussay and coworkers [37]. Although we
observed a significant correlation between the expression of
the two miRNAs from the 13q14.3 cluster, miR-15a and miR-
16-5p (Spearman coefficient ratio 0.5878), there was no
significant correlation between their expression and
D13S319 deletion assessed by FISH. As 13q14.3 deletion is
thought to be the main reason of miR-15a and miR-16-1
deficiency in CLL lymphocytes, our results may point to other
blood cells as the source of serum miR-15a [17].
We confirmed the crucial role of the four discussed
miRNAs in CLL by the observation that their serum expres-
sion is significantly associated with selected prognostic
factors (Table 4). Lower miR-34a expression was observed
in the adverse prognostic group of CD38-positive patients;
patients with TP53 deletion/mutation and RB1 deletion were
characterized by higher miR-155-5p expression. The latter
group presented also with higher miR-150-5p expression.
miR-15a-5p was expressed at a lower level in patients with
CD38+ and those harboring 17p deletion/TP53 mutation.
miR-31-5p was the only one of the circulating miRNAs of
the highest expression a priori associated exclusively with T
cell differentiation (Supplementary Table S3). Its locus has
been mapped to chromosome 9p21.3. Aberrant expression
of miR-31 was described in many solid tumors [62–64]. In
some, like melanomas, its deficiency is associated with dele-
tion, and the ectopic expression inhibits cell migration and
invasion [65]. Wang and coworkers reported decreased miR-
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31 expression in aggressive bladder cancer [64]. On the
contrary, miR-31 overexpression in colon cancer is associated
with the increased proliferation potential, and in lung adeno-
carcinoma, it was reported to predict lymph node metastases
[62, 63]. Results of our study showed that serum miR-31-p
expression is lower in patients with 11q/ATM deletion. We
have found no data about the role of miR-31 in CLL.
However, some conception may come from the study by
Rouas and colleagues. They have found that miR-31 negatively
regulates FOXP3 mRNA in Tregs [66]. FOXP3 is considered
as master regulator of Treg development and function, and its
deletions or mutations are associated with severe, even lethal
autoimmune diseases [66]. CLL patients are characterized by
an increased absolute number of Tregs as compared with
healthy individuals. Moreover, a progressive increase of Tregs
was reported in advanced stages of the disease and in patients
with autoimmune cytopenias [3]. Contrasting data concern the
role of Tregs in CLL: they were found to express cytolytic
markers and kill autologous B cells, but may also suppress
antitumor response [66]. Considering the above facts, the sig-
nificance of serum miR-31 overexpression in CLL patients
needs further investigation.
The analysis of the association of general serum
miRNA expression with clinical, molecular, and cytoge-
netic prognostic factors has shown that CD38 expression
discriminated the expression of 20 miRNAs (23.8 % of all
analyzed). Fourteen miRNAs (16.7 %) were expressed
differently depending on the status of chromosome 12;
age, B2M level, and status of RB1 gene each discriminat-
ed the expression of nine miRNAs (Table 4).
While analyzing the general miRNA expression, we were
surprised to discover that neither IGVH gene status nor
ZAP70 expression was a significant discriminating factor, as
they were described to be important for cellular miRNA ex-
pression in CLL patients [37, 38, 40, 67]. ZAP70 expression
status was reported by Moussay to affect also plasma miRNA
expression [37]. In our study, both ZAP70 and IGVH status
discriminated the expression of only one miRNA each: miR-
182-5p (P = 0.0304) and miR-28b-3p (P = 0.0033), respec-
tively. SerummiRNA expression may differ from lymphocyte
expression pattern because miRNA molecules secreted by
other blood cells bias it. Instead, the discrepancy between
our results and that of Moussay et al. may be a consequence
of a little different methodology: they have isolated miRNA
from plasma and profiled the expression by means of Taq
miRNA low-density array from Applied Biosystems [37].
Our results may be also affected in a way by the limited
number of patients. Besides, as reported previously, none of
the miRNA expression profiles in CLL published to date are
identical—this may also reflect the heterogeneity of the
disease [40].
In this study, for the first time,NOTCH1 genemutation was
considered in miRNA profiling analysis. The role ofNOTCH1
gene mutations in CLL was reviewed by us before [27]. It is a
relatively new prognostic factor correlated with shorter time-
to-first treatment, which may be an important clue for clini-
cians [68]. When the expression of the whole pool of studied
miRNAs was analyzed, only two miRNAs were found to dis-
criminate betweenNOTCH1mutated and NOTCH1wild-type
patients: miR-132-3p and miR-146-5p were expressed at a
lower level in the latter group (Table 4). Both of them, how-
ever, are important for leukemogenesis. The recent study by
Tavolaro and coworkers points to miR-132 as one of two
miRNAs upregulated in CLL lymphocytes following BCR
stimulation. They linked its overexpression with RB1/E2F
and TP53 cascades and proproliferative effects [69]. miR-
146, on the other hand, is a well-known regulator of both
innate and adaptive immune responses which was implicated
both in lymphomagenesis and tumor suppression. Its overex-
pression was reported in splenic marginal zone lymphomas
and in diffuse large B cell lymphoma (DLBCL) [70].
Analysis of miRNAs whose expression differentiated
patients in several prognostic groups revealed one, miR-182-
5p, common for four groups (Table 5). It was also the only
miRNA discriminating ZAP70+ and ZAP70− patients. To
date, miR-182 was not described to be associated with CLL.
However, it was found to act as an oncogene in lymphoblastic
malignancies through regulation of FOXO3A gene, a member
of forkhead transcriptional factor family, which has been
implicated in tumor suppression and glucocorticoid-induced
apoptosis [71].
When patients with and without indications for treatment
were analyzed, a lower expression of some miRNAs in the
former group was found (Table 4). Among them was miR-
181a-5p, whose underexpression in CLL was described to
correlate with shorter overall survival and treatment free
survival [72].
The comparison of functionally grouped miRNA expres-
sion between CLL patients and healthy individuals has shown
that alterations in expression pattern involve all functional
groups, and most of them correlate with prognostic factors
(Tables 6 and 7). This confirms the involvement of various
cell populations in the pathogenesis of the disease. Three
groups that were mostly associated with prognostic factors
were miRNAs linked with germinal center B cells, T cell
activation, and double negative lymphocytes.
Characteristic histological features of CLL are proliferation
centers (PCs) located within secondary lymphatic organs,
which contain prolymphocytes, paraimmunoblasts, T
lymphocytes, nurse-like cells, and dendritic cells. Within
proliferation centers, B cells may proliferate and undergo
selection and clonal expansion in a T-dependent manner
[73]. In many CLL cases, the number of proliferation centers
is increased (PC-rich cases) which is associated with adverse
prognosis; PCs serve as reservoir of leukemic cells and the
source of minimal residual disease [41]. As the cells within
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PCs are more activated than circulating cells, it is quite possi-
ble that the profile of circulating miRNAs associated with cell
activation will differ from the profile of peripheral blood leu-
kemic cells.
Here we show that the level of expression of these miRNAs
(especially related to germinal center B cells and T cell activa-
tion) is lower in some adverse prognostic groups: in older pa-
tients, CD38 positive, with unmutated IGVH genes, highWBC,
high B2M level, and 11q/ATM deletion (Tables 6 and 7). The
presented miRNA expression profile confirms the favorable
prognostic significance of trisomy 12—in patients bearing this
aberration, the expression of the discussed miRNAs was lower.
When the expression of functional miRNA groups was an-
alyzed, NOTCH1 status was also found to be an important
discriminating factor (Tables 6 and 7). It affected the expression
of all miRNAs associated with B cell differentiation and acti-
vation as well as this was linked with T cell activation, Tregs,
and early stages of T cell differentiation. As NOTCH1 activat-
ing mutations in CLL are thought to contribute to apoptosis
resistance via activation of the nuclear factor-κB (NF-κB) path-
way and the AKT pathway, it is quite reasonable that the status
of this gene may impact miRNA and gene expression profile
[74]. The expression of miRNAs analyzed in this study was
higher in patients bearing NOTCH1 mutation.
What is noteworthy, our results show that the subpopulation
of Tregs seems to be equally involved in CLL development.
The expression of miRNAs differently expressed in Tregs was
found to be significantly associated with patients’ age, WBC,
CD38 expression, and B2M level, as well as with deletion of
11q, mutational status of NOTCH1 and IGVH, and trisomy 12
(Tables 6 and 7). The association of Treg number with CLL
progression and coexisting immunodeficiency was reported by
Lad and coworkers [3]. A recent study by Jitschin and col-
leagues has shed some light on the mechanisms of Treg induc-
tion. They have focused on the further component of CLL
microenvironment, described as myeloid-derived suppressor
cells (MDSCs) [4]. MDSCs represent a heterogeneous popula-
tion of myeloid progenitors and precursors of granulocytes,
macrophages, and dendritic cells [75]. MDSC differentiation
is driven by CLL lymphocytes; they act by inhibiting T cell
responses and promoting induction of regulatory T cells. The
latter effect was linked to the fact that MDSCs produce an
immunomodulatory cytokine indoleamine-2,3-dioxygenase
(IDO), the first and rate-limiting enzyme of tryptophan catabo-
lism through the kynurenine pathway [4]. However, we
hypothesize that miRNA molecules circulating in peripheral
blood of CLL patients may also induce Tregs.
Conclusions
Chronic lymphocytic leukemia is a very heterogeneous
disease and its pathogenesis is complex both at the molecular
and the cellular level. Some pieces of the puzzle were now
completed, but yet there are many to discover. Although
subsequent studies on larger patient cohort are necessary, the
presented results of serum miRNA expression profiling have
confirmed that CLL should be considered as disease of the
blood, bone marrow, and secondary lymphatic organs.
Circulating miRNAs may be released by leukemic lympho-
cytes to tout the neighboring cells. And vice versa, all by-
standing cells may potentially influence leukemic lympho-
cytes and help them to divide and avoid apoptosis. Thus, the
studies of the mechanisms involved in CLL development, as
well as the design of novel therapeutic strategies, require a
holistic approach involving focus on all B and T lymphocyte
populations, together with stromal cells, nurse-like cells,
MDSCs, and other cells composing the microenvironment.
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